Vaccines

A new alcohol-free, no-refrigeration blood pressure liquid aims to transform daily treatment for children, reflecting a key industry shift.

Astellas and Pfizer's PADCEV-Keytruda combo, showing a 47% drop in recurrence risk, earns FDA Priority Review, offering new hope for bladder cancer patients.

A Shanghai-based firm's new approach could create cancer-fighting cells inside the body, slashing costs and wait times for CAR-T therapy.

New preclinical data reveals a novel drug, rinzimetostat, may overcome treatment resistance in prostate cancer by targeting a unique molecular switch.

A landmark real-world study from England shows maternal RSV vaccination slashes infant hospitalizations, validating a powerful new shield for newborns.

Interim study results suggest a common food product may significantly enhance the effectiveness of modern cancer treatments, heralding a new era of care.

New clinical consensus on ammonia and scrutiny of a standard antibiotic are creating a perfect storm for Yaqrit's promising new liver disease treatments.

At AACR 2026, CREATE Medicines debuts its RetroT platform, an all-RNA system for stable gene delivery that avoids viral vectors and reshapes cell therapy.

A European consortium has won €1.3M to develop a precision therapy for chronic urticaria, offering new hope for millions with uncontrolled symptoms.

New data reveals Mapi Pharma's long-acting GA Depot stabilizes disability in both relapsing and progressive MS, poised for a 2027 European launch.

Patients, doctors, and researchers unite for a grueling ride across Iceland, raising funds and hope for a future free from multiple myeloma.

A novel drug for a debilitating stomach disorder is set for a major reveal, offering hope to millions with limited and often risky treatment options.

A new survey shows nearly half of employers are considering international drug sourcing, a legally murky strategy, as cost control dethrones talent retention.

A novel immunotherapy tames a potent but toxic cancer-fighting agent by locking it inside tumors, offering new hope for patients with resistant cancers.

With founder Frédéric Mascha as Executive Chairman and new CEO Renaud Sermondade, Juvisé Pharmaceuticals is poised for major M&A-fueled global expansion.

Backed by Bain Capital and a veteran team, the new biotech has a de-risked pipeline from Bristol Myers Squibb aimed at transforming care for lupus and more.

A new FDA-approved powder form of a common blood pressure drug aims to solve a daily struggle for the elderly, children, and tube-fed patients.

With $108M in new funding, Terremoto Biosciences advances a novel class of drugs designed to overcome the toxicities of past cancer treatments.

With a fresh $28M investment, Verismo Therapeutics is set to unveil groundbreaking KIR-CAR data, aiming to revolutionize CAR T therapy for solid tumors.

Shanghai's SinoUnited Health is attracting global patients with advanced care like CAR-T therapy at a fraction of US prices, challenging medical tourism hubs.